Rivfloza (Nedosiran)

$41,611.88

Rivfloza (nedosiran) is a prescription medicine for the treatment of children (9+) and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function1.

Rivfloza (nedosiran) is approved by the FDA in the USA 2.

What is Rivfloza (nedosiran) for?

Rivfloza (nedosiran) is a prescription medicine indicated to lower urinary oxalate levels in children (9+) and adults with primary hyperoxaluria type 1 (PH1). The medicine is intended for patients with relatively preserved kidney function (e.g. eGFR  ≥ 30 mL/min/1.73m2) [1].

Rivfloza (nedosiran) is available as an injection (160 mg/mL) in these forms:

  • 80 mg (0.5 mL) single-dose vial;
  • 128 mg (0.8 mL) single-dose pre-filled syringe;
  • 160 mg (1 mL) single-dose pre-filled syringe [1].

How does Rivfloza (nedosiran) work?

Nedosiran is a type of drug known as a double-stranded siRNA, which is linked to special sugar molecules called GalNAc aminosugars. When nedosiran is given as an injection under the skin, these sugars help it to specifically target and enter liver cells by attaching to certain liver cell receptors called asialoglycoprotein receptors (ASGPR).

Once inside the liver cells, nedosiran works to decrease the levels of a specific enzyme called lactate dehydrogenase (LDH) by breaking down the messenger RNA (mRNA) that instructs the cell to produce LDH. This process is known as RNA interference.

By reducing the amount of LDH in the liver, nedosiran also lowers the production of oxalate, a substance that can contribute to kidney stones and other health issues. In this way nedosiran helps to lessen the overall oxalate levels in the body [1].

Where has Rivfloza (nedosiran) been approved?

Rivfloza (nedosiran) is currently approved by the FDA in the USA [2].